Diagnosis of Liver Disease
暫譯: 肝病診斷

本書指導從業人員評估有肝臟問題的病人。重點在於宏觀和微觀病理學在闡明病因及識別影像發現中可能導致更複雜鑑別診斷的混淆特徵的角色。如果適用，將說明光學和電子顯微鏡檢查的角色，以及特定染色和分子技術的作用。此外，簡要總結每種肝病的概念並提供最新資料，並清楚描述診斷、治療和病因學中未解決的問題。本書的方式是實用的，重點在於評估示例案例，同時展示橫斷面影像（超聲波、電腦斷層掃描、磁共振成像和血管造影）、病理發現和腹腔鏡影像。診斷和治療以有用的表格總結，臨床表現與影像分析及病理發現的關聯在鑑別診斷和治療中被顯示為重要。作者由國際知名專家組成，本書將成為全球醫學生、醫生、內科醫師、肝臟病專家、胃腸病專家、放射科醫生和病理學家的有用資訊來源。

Dr. Etsuko Hashimoto is a Professor of Hepatology and Gastroenterology at Tokyo Women's Medical University. She received her MD from Tokyo Women's Medical University. She had the privilege of studying liver pathology under Professor Ludwig, who is a renowned pathologist at MAYO Clinic, from 1987 to 1991. Professor Ludwig is well known as he established the concepts and the definition of NASH. She has served on numerous committees for national and international societies including the Asia-Pacific Working Party on NAFLD. She is the author of the recent Japanese and Asia Practice Guideline for NAFLD/NASH. At present, her primary area of interest is in the field of NASH, specifically in elucidation of the characteristics of HCC in NASH. She has won multiple awards, both at the university, local, and national level.

Dr. Kwo is currently Professor of Medicine and Director of Hepatology at the Stanford University where he joined the faculty in November 2016. Prior to joining the faculty at Stanford, he was at Indiana University for 21 years where he served as the Medical Director of Liver Transplantation. He received his MD from Wayne State University School of Medicine, his Internal Medicine training at University of Maryland, and his Gastroenterology/Hepatology training at Mayo Clinic Rochester. He has served on numerous committees for national and international societies including the Nominating Committee and Clinical Research Committee for the AASLD and is Trustee for the ACG. He has distinguished himself in the field of chronic Hepatitis C and has served as the PI for multiple seminal trials in the treatment of hepatitis C. He is the author of the recent ACG Practice Guideline Evaluation of Abnormal Liver Chemistries. He has won multiple awards, both at the university, local, and national level.

Dr. Arief Suriawinata is a Professor of Pathology and Laboratory Medicine at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA. He received his medical doctor degree from University Indonesia, followed by residency in pathology at The Mount Sinai Hospital, New York, New York and fellowships in oncologic pathology and gastrointestinal pathology at Memorial Sloan Kettering Cancer Center, New York, New York. Dr. Suriawinata's research interests include liver and pancreatobiliary malignancy and gastrointestinal diseases. He is a member of Laennec International Liver Pathology Society. Dr. Suriawinata is board certified in Anatomic and Clinical Pathology and Clinical Informatics.

Dr. Tsui graduated from the University of Hong Kong. After receiving training in Queen Elizabeth Hospital, HK, and Royal Free Hospital, UK, he was appointed Consultant Pathologist in Caritas Medical Centre and then the Director of the pathology department. He is a Past President of the Hong Kong Division of the International Academy of Pathology and a member of the Elves International Liver Pathology Study Group. His main academic interest is in hepatobiliary and gastrointestinal pathology. He has edited a liver pathology book, and published over 60 peer-reviewed articles and over 30 book chapters.

Dr. Iwai is currently Director in Iwai Clinic, Division of Gastroenterology, Hepatology and Internal Medicine. Prior to the Director he was at Kyoto Prefectural University School of Medicine, Department of Gastronenterology and Hepatology for 38 years where he served as an associated Professor. He received his MD from Kyoto Prefectural University School of Medicine, and clinical practice for Internal Medicine, Gastroenterology and Hepatology was trained in University, Municipal and Red Cross Hospital. His PhD was endowed by clarifying biological significane of AFP-positive cells in hepatocarcinogenesis in 1983 while he investigated protein-synthesis in liver of pathological conditions, relationship of HBV with hepatoma, roles of hepatic junctional complex for development or malignant transformation of hepatoma cells and gene therapy for hepatoma. He has distinguished himself in the field of autoimmune liver diseases and malignant tumors in liver. He was a member of AASLD and IASLD and served as a committee or board director in internal Conference of Gastroenterology and Hepatology. He won awards from national Society of Hepatology, local goverment and foundation and got budget for research at local and national level.

Dr. Etsuko Hashimoto 是東京女子醫科大學的肝臟病學與胃腸病學教授。她在東京女子醫科大學獲得醫學博士學位。從1987年到1991年，她有幸在著名病理學家Ludwig教授的指導下學習肝臟病理學，Ludwig教授在MAYO Clinic享有盛譽，並以建立NASH的概念和定義而聞名。她曾在多個國內外學會的委員會中任職，包括亞太地區NAFLD工作小組。她是最近發表的日本和亞洲NAFLD/NASH實踐指導方針的作者。目前，她的主要研究領域是NASH，特別是闡明NASH中HCC的特徵。她在大學、地方和國家層面上獲得了多個獎項。

Dr. Kwo 目前是斯坦福大學的內科教授及肝臟病學主任，自2016年11月加入該校教職。在加入斯坦福之前，他在印第安納大學工作了21年，擔任肝臟移植的醫療主任。他在韋恩州立大學醫學院獲得醫學博士學位，並在馬里蘭大學接受內科訓練，在Mayo Clinic Rochester接受胃腸病學/肝臟病學訓練。他曾在多個國內外學會的委員會中任職，包括AASLD的提名委員會和臨床研究委員會，並擔任ACG的受託人。他在慢性C型肝炎領域中表現卓越，並擔任多項C型肝炎治療的開創性試驗的首席研究員。他是最近發表的ACG異常肝化學評估實踐指導方針的作者。他在大學、地方和國家層面上獲得了多個獎項。

Dr. Arief Suriawinata 是美國新罕布什爾州達特茅斯-希契醫療中心的病理學與實驗室醫學教授。他在印尼大學獲得醫學博士學位，隨後在紐約的西奈山醫院進行病理學住院醫師訓練，並在紐約的紀念斯隆-凱特琳癌症中心接受腫瘤病理學和胃腸病理學的研究員訓練。Dr. Suriawinata的研究興趣包括肝臟和胰膽道惡性腫瘤及胃腸疾病。他是Laennec國際肝臟病理學會的成員。Dr. Suriawinata在解剖病理學和臨床病理學及臨床資訊學方面均獲得了專業認證。

Dr. Tsui 畢業於香港大學。在香港的伊莉莎白女王醫院和英國的皇家自由醫院接受訓練後，他被任命為明愛醫療中心的顧問病理學家，隨後成為病理學部門的主任。他曾擔任國際病理學學院香港分會的前會長，並且是Elves國際肝臟病理學研究小組的成員。他的主要學術興趣在於肝膽和胃腸病理學。他編輯了一本肝臟病理學書籍，並發表了超過60篇同行評審的文章和超過30章書籍章節。

Dr. Iwai 目前是Iwai診所的主任，專注於胃腸病學、肝臟病學和內科。在擔任主任之前，他在京都府立醫科大學的胃腸病學和肝臟病學系工作了38年，擔任副教授。他在京都府立醫科大學獲得醫學博士學位，並在大學、市立醫院和紅十字醫院接受內科、胃腸病學和肝臟病學的臨床訓練。他的博士學位是通過闡明AFP陽性細胞在肝癌發生中的生物學意義而獲得的，這項研究於1983年進行，研究內容包括病理狀況下肝臟的蛋白質合成、HBV與肝癌的關係、肝臟交界複合體在肝癌細胞發展或惡性轉化中的作用，以及肝癌的基因治療。他在自身免疫性肝病和肝臟惡性腫瘤領域中表現卓越。他曾是AASLD和IASLD的成員，並在胃腸病學和肝臟病學的內部會議中擔任委員或董事。他獲得了國家肝臟病學學會、地方政府和基金會的獎項，並獲得了地方和國家層面的研究預算。